Survodutide for MASH: The Glucagon/GLP-1 Dual Agonist's Liver Program

Most of the incretin conversation centers on weight and glucose. Survodutide is interesting because its second target — the glucagon receptor — points somewhere else: the liver. This research log walks through what the published data actually show for survodutide in MASH (metabolic dysfunction-associated steatohepatitis), where the program stands in 2025-2026, and why the liver effort is deliberately kept separate from the drug's obesity work. Survodutide is investigational for MASH; it is not FDA-approved for this or any indication as of this writing. See /peptides/survodutide and /fda-status for our tracked status pages.

Research log: what we checked

We worked from the Phase 2 trial published in the New England Journal of Medicine (Sanyal et al., NEJMoa2401755, 2024), Boehringer Ingelheim's and Zealand Pharma's own press releases, and clinical-news coverage of the FDA action. Where numbers appear below, they come from those primary reports, not from secondary summaries.

The molecule and who develops it

Survodutide (BI 456906) is a once-weekly subcutaneous peptide that acts as a dual agonist at the glucagon receptor and the GLP-1 receptor. It was originated by Zealand Pharma and licensed to Boehringer Ingelheim, which is solely responsible for its global development and commercialization; Zealand is eligible for development, regulatory, and commercial milestones plus royalties on any future sales.

That dual mechanism is the whole thesis. The GLP-1 arm drives appetite suppression, satiety, and glycemic effects — the familiar incretin toolkit. The glucagon arm is what differentiates it for liver disease: glucagon-receptor activation is thought to increase energy expenditure and, importantly, to act directly on hepatocytes to raise fatty-acid oxidation and reduce hepatic fat. In other words, part of survodutide's proposed liver benefit is meant to be independent of weight loss alone. That rationale is why a glucagon/GLP-1 co-agonist is an attractive MASH candidate rather than "just another" weight-loss drug.

Phase 2 MASH results (NEJM 2024)

The Phase 2 trial randomized adults with biopsy-confirmed MASH and fibrosis stages F1 through F3 to survodutide 2.4 mg, 4.8 mg, or 6.0 mg once weekly, or placebo, over 48 weeks (a 24-week dose-escalation phase followed by 24 weeks of maintenance).

The primary endpoint — histologic improvement in MASH with no worsening of fibrosis — was met across the survodutide doses:

Secondary endpoints moved in the same direction. Reported benefits included MASH resolution without worsening of fibrosis and improvement of fibrosis by at least one stage occurring more often than on placebo, alongside large reductions in liver fat measured by MRI-PDFF at the higher doses. Gastrointestinal side effects (nausea, vomiting, diarrhea) were the most common adverse events — consistent with the GLP-1 class — and were a driver of the escalation-then-maintenance dosing design.

The headline framing matters: this is Phase 2, biopsy-based, and dose-ranging. It establishes a signal on histology, not a confirmed clinical-outcomes benefit, and it is exactly the kind of result that a much larger Phase 3 exists to confirm or temper.

FDA Breakthrough Therapy designation

On the strength of the Phase 2 data, the U.S. FDA granted survodutide Breakthrough Therapy designation (announced late 2024) for the treatment of adults with non-cirrhotic MASH and moderate-to-advanced (stage F2 or F3) fibrosis. Breakthrough Therapy status is a process tool — it can enable more intensive FDA guidance and potentially expedited review for therapies that show substantial improvement over available options on a preliminary basis. It is not an approval and not an efficacy verdict; it signals the agency considers the early data promising enough to prioritize.

Phase 3: the LIVERAGE program (2025-2026)

The confirmatory work is the LIVERAGE program, comprising two global Phase 3 trials:

The first part of LIVERAGE reads out on histology at 52 weeks (MASH resolution without worsening of fibrosis, and fibrosis improvement without worsening of MASH). A second part is designed to run for roughly seven years to assess liver-related clinical events and all-cause mortality — the outcomes that ultimately define whether histologic change translates into patients living longer and better. As of 2025-2026 these trials are enrolling/ongoing; no Phase 3 efficacy results are available yet.

Distinct from the obesity program

It is easy to conflate the two, so keep them separate. Survodutide's obesity development is the SYNCHRONIZE Phase 3 program, where SYNCHRONIZE-1 reported average weight loss of up to 16.6% at 76 weeks versus placebo. The MASH liver development is LIVERAGE, with liver histology and liver-related outcomes as its endpoints. The obesity and liver programs share a molecule but have different trials, different primary endpoints, and different regulatory paths — a Breakthrough designation in MASH says nothing about obesity approval, and vice versa.

Bottom line

Survodutide's glucagon/GLP-1 design gives it a mechanistic reason to target liver fat directly, and its Phase 2 MASH data plus FDA Breakthrough Therapy designation are why it's worth tracking. But the deciding evidence — the LIVERAGE Phase 3 histology and long-term outcomes — is still pending. Until then, it remains investigational for MASH.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.